The Food and Drug Administration (FDA) on Wednesday approved the updated version of Pfizer's and Moderna's COVID-19 vaccines for this upcoming respiratory viral season, but limited the approval to seniors and people at a high risk of severe infections, reducing the eligibility pool.

Moderna announced the FDA approved its updated Spikevax vaccine, which will target the LP.8.1 variant of SARS-CoV-2.

"The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older," the company said in a press release.

Pfizer's updated vaccine, called Comirnaty, was approved for adults 65 and older as well as people between 5 and 64

See Full Page